Suppr超能文献

五试点耐多药结核病规划中耐多药结核病患者的细菌学监测。

Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects.

机构信息

Division of Tuberculosis Elimination, US Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.

出版信息

Int J Tuberc Lung Dis. 2011 Oct;15(10):1315-22. doi: 10.5588/ijtld.10.0221.

Abstract

BACKGROUND

Multidrug-resistant tuberculosis programs in DOTS-Plus pilot sites in five countries.

OBJECTIVES

To calculate sputum conversion time and its relationship to treatment outcome, document the frequency of culture reversions and examine concordance of smear and culture to assess the potential consequences of monitoring by smear microscopy alone.

DESIGN

Retrospective cohort analysis of 1926 patients receiving individualized, second-line therapy.

RESULTS

Among 1385 sputum culture-positive cases at baseline, 1146 (83%) experienced at least one culture conversion during treatment. Conversion, however, was not sustained in all patients: 201 (15%) experienced initial culture conversion and at least one subsequent culture reversion to positive; 1064 (77%) achieved sustained culture conversion. Median time to culture conversion was 3 months. Among 206 patients whose nal conversion occurred 7-18 months after the initiation of therapy, 71% were cured or had completed treatment.

CONCLUSIONS

Prolonged treatment for patients with delayed conversion may be beneficial, as 71% of late converters still achieved cure or completed treatment. This has implications for programs with de ned end points for treatment failure. The interval between rst and nal conversion among patients whose initial con- version is not sustained raises concern with respect to the ongoing debate regarding duration of treatment and the definition of cure.

摘要

背景

在五个国家的 DOTS-Plus 试点地区实施耐多药结核病规划。

目的

计算痰培养转阴时间及其与治疗结局的关系,记录培养物复阳的频率,并检查涂片和培养的一致性,以评估仅通过痰涂片镜检监测的潜在后果。

设计

对接受个体化二线治疗的 1926 例患者进行回顾性队列分析。

结果

在基线时的 1385 例痰培养阳性病例中,有 1146 例(83%)在治疗过程中至少经历过一次培养物转阴。然而,并非所有患者的转阴都得到维持:201 例(15%)患者经历了初始培养物转阴,随后至少有一次培养物再次转为阳性;1064 例(77%)患者实现了持续培养物转阴。痰培养转阴的中位时间为 3 个月。在 206 例治疗开始后 7-18 个月痰培养最终转阴的患者中,有 71%治愈或完成了治疗。

结论

对于那些转阴延迟的患者,延长治疗时间可能是有益的,因为 71%的晚期转阴患者仍实现了治愈或完成了治疗。这对具有明确治疗失败终点的项目有影响。对于初始转阴不能维持的患者,首次和最终转阴之间的间隔时间引起了人们对治疗持续时间和治愈定义的持续争论的关注。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验